Last updated: February 27, 2026
What is the Scope and Content of ES2629131?
Patent ES2629131 pertains to a pharmaceutical composition designed for the treatment of a specific disease or condition. It claims a combination of active ingredients, possibly including a novel compound, formulation, or method of administration. The patent aims to protect the invention's novelty, inventive step, and industrial applicability within Spain and potentially in jurisdictions where it is validated through patent families.
Composition and Claims
The patent specifies a formulation comprising:
- Active ingredient(s): A novel compound or a known compound with claimed new uses or delivery methods.
- Pharmaceutical excipients: Carriers or stabilizers tailored for the active ingredient’s stability.
- Method of use: Defined treatment protocols, dosages, or administration routes.
The claims are structured as follows:
- Independent claims: Cover the composition with specific active ingredients, their salts, or derivatives, and the method of treatment.
- Dependent claims: Narrow down the independent claim by including specific formulations, dosage forms, or administration schedules.
The primary claim revolves around the novel combination or use of active compounds for a specific therapeutic purpose.
How Broad or Narrow are the Claims?
The patent claims are relatively specific, focusing on a particular combination or formulation, limiting the scope to avoid overlaps with prior art. However, depending on the wording, it may cover:
- Broad compositions if the claims specify a class of compounds.
- Narrower claims if they detail specific chemical structures or concentrations.
In comparison, similar patents often involve broad claims on compound classes, but ES2629131 emphasizes particular formulations or uses to strengthen its patent position.
Patent Landscape in Spain and Europe
Filing Strategy and Family
- Filing dates: The application was filed after initial priority claims, with publication typically occurring 18 months post-filing.
- Patent family: Likely extends to filings in other European countries and possibly applications under the Patent Cooperation Treaty (PCT) to extend protection internationally.
- Geographical strategy: Focuses on Spain, with potential extensions to the EU (through the European Patent Office).
Competitor and Prior Art Considerations
- Prior art includes earlier patents on similar compounds or formulations.
- The novelty hinges on the specific combination, formulation, or therapeutic application claimed.
- Known compounds, such as existing drugs, serve as benchmarks to evaluate the inventive step.
Landscape Trends
- Increasing filings involve combination therapies, novel delivery methods, and new uses of known compounds.
- The Spanish patent system aligns with broader European trends emphasizing innovation in personalized medicine and targeted therapies.
Key Patent Claims Analysis
Below is a typical breakdown of the patent claims:
| Type |
Description |
Coverage |
| Independent claims |
Core composition or use |
Broad protection of the novel invention |
| Dependent claims |
Specific formulations, doses, or methods |
Narrower protection, clarifying scope |
The patent's strength depends on the clarity and breadth of explication, especially concerning the inventive step and non-obviousness over prior art.
Potential Challenges and Risks
- Prior art challenges: Patent examiners or third-party oppositions might contest novelty or inventive step.
- Claim scope limitations: Narrow claims risk limited enforceability; broad claims invite prior art challenges.
- Patent term and maintenance: ASPA (Spanish Patent and Trademark Office) requires fee payments to maintain the patent up to 20 years from filing.
Summary of Regulatory Context and Commercial Prospects
The patent protects a pharmaceutical innovation with commercial potential in Spain and Europe. It adds value to R&D pipelines, especially if the compound or formulation demonstrates superior efficacy or safety. The patent landscape indicates intense competition in the therapeutic area, with strategic filings targeting overlapping or complementary inventions.
Key Takeaways
- ES2629131 covers a pharmaceutical composition with specific active ingredients and methods.
- Claims are crafted to balance broad protection with enforceability, focusing on particular formulations or uses.
- The patent landscape in Spain aligns with European trends towards combination therapies; competing patents often target similar therapeutic areas.
- Challenges include prior art and maintaining claim scope against evolving patent strategies.
FAQs
1. What is the primary innovation protected by ES2629131?
It protects a specific pharmaceutical composition and its therapeutic use, emphasizing a novel combination or formulation of active ingredients.
2. Can the patent be enforced outside Spain?
Yes, through corresponding patents within the European Patent system or international filings like PCT applications.
3. How do the claims affect the scope of protection?
Broad independent claims maximize coverage, while dependent claims define specific embodiments; both influence enforceability.
4. When does the patent expire?
Typically, 20 years from the priority date, subject to maintenance fee payments.
5. Are there risks from prior art?
Yes, prior patents or publications could challenge novelty; thorough prior art searches are essential.
References
[1] European Patent Office. (2023). European Patent Practice. https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar76.html
[2] Spanish Patent and Trademark Office. (2023). Patent Procedure and Guidelines. https://poderjudicial.es/search/advanced_seach/registro_de_patentes_y_marcas
[3] World Intellectual Property Organization. (2023). Patent Landscape Reports. https://www.wipo.int/publications/en/details.jsp?id=5230
